AR045917A1 - Mezclas de oligosacaridos derivados de la heparina, su preparacion y las composiciones farmaceuticas que las contienen - Google Patents
Mezclas de oligosacaridos derivados de la heparina, su preparacion y las composiciones farmaceuticas que las contienenInfo
- Publication number
- AR045917A1 AR045917A1 ARP040102549A ARP040102549A AR045917A1 AR 045917 A1 AR045917 A1 AR 045917A1 AR P040102549 A ARP040102549 A AR P040102549A AR P040102549 A ARP040102549 A AR P040102549A AR 045917 A1 AR045917 A1 AR 045917A1
- Authority
- AR
- Argentina
- Prior art keywords
- mixtures
- activity
- pharmaceutical compositions
- compositions containing
- oligosaccharides
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title abstract 3
- 229920000669 heparin Polymers 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000694 effects Effects 0.000 abstract 3
- 229920001542 oligosaccharide Polymers 0.000 abstract 3
- 150000002482 oligosaccharides Chemical class 0.000 abstract 3
- 229960002897 heparin Drugs 0.000 abstract 2
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 150000001340 alkali metals Chemical class 0.000 abstract 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 1
- -1 alkaline earth metal salt Chemical class 0.000 abstract 1
- 230000001858 anti-Xa Effects 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000014508 negative regulation of coagulation Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Mezclas de oligosacáridos derivados de la heparina que tiene un peso molecular medio de 1.800 a 2.400 Daltones, caracterizadas por una gran actividad aXa y una ausencia de actividad anticoagulante (aIIa), a su procedimiento de preparación y a las composiciones farmacéuticas que las contiene. Reivindicación 1: Mezclas de oligosacáridos que poseen la estructura general de los polisacáridos constitutivos de la heparina y que presentan las siguientes características: un peso molecular medio de 1.800 a 2.400 Daltones; una actividad anti-Xa comprendida entre 190 UI/mg y 450 UI/mg; una actividad anti-IIa nula o prácticamente nula. Quedando entendido que los oligosacáridos constitutivos de las mezclas: contienen de 2 a 16 retos sacarídicos; tienen un resto de ácido urónico-4,5 insaturado 2-O-sulfato en uno de sus extremos; y contienen hexasacárido de grupo de fórmulas (1), en forma de una sal de metal alcalino o alcalino-térreo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0309041A FR2857971B1 (fr) | 2003-07-24 | 2003-07-24 | Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR045917A1 true AR045917A1 (es) | 2005-11-16 |
Family
ID=33561051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102549A AR045917A1 (es) | 2003-07-24 | 2004-07-19 | Mezclas de oligosacaridos derivados de la heparina, su preparacion y las composiciones farmaceuticas que las contienen |
Country Status (39)
| Country | Link |
|---|---|
| EP (1) | EP1651677B1 (es) |
| JP (1) | JP4865552B2 (es) |
| KR (1) | KR101125517B1 (es) |
| CN (1) | CN1852926B (es) |
| AR (1) | AR045917A1 (es) |
| AT (1) | ATE487741T1 (es) |
| AU (1) | AU2004259111B2 (es) |
| BR (1) | BRPI0412850A (es) |
| CA (1) | CA2533555A1 (es) |
| CR (1) | CR8201A (es) |
| CY (1) | CY1111165T1 (es) |
| DE (1) | DE602004030015D1 (es) |
| DK (1) | DK1651677T3 (es) |
| EC (1) | ECSP066305A (es) |
| ES (1) | ES2355827T3 (es) |
| FR (1) | FR2857971B1 (es) |
| GT (1) | GT200400145A (es) |
| HN (1) | HN2004000250A (es) |
| IL (1) | IL173206A (es) |
| MA (1) | MA27928A1 (es) |
| ME (1) | MEP11608A (es) |
| MX (1) | MXPA06000336A (es) |
| MY (1) | MY136769A (es) |
| NO (1) | NO20060821L (es) |
| NZ (1) | NZ544717A (es) |
| OA (1) | OA13197A (es) |
| PA (1) | PA8606801A1 (es) |
| PE (1) | PE20050246A1 (es) |
| PL (1) | PL1651677T3 (es) |
| PT (1) | PT1651677E (es) |
| RS (1) | RS20060044A (es) |
| RU (1) | RU2346005C2 (es) |
| SI (1) | SI1651677T1 (es) |
| TN (1) | TNSN06025A1 (es) |
| TW (1) | TWI369208B (es) |
| UA (1) | UA89356C2 (es) |
| UY (1) | UY28435A1 (es) |
| WO (1) | WO2005010051A2 (es) |
| ZA (1) | ZA200600657B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7589145B2 (en) | 2004-04-15 | 2009-09-15 | Exxonmobil Chemical Patents Inc. | Syndiotactic rich polyolefins |
| CA2652205A1 (en) * | 2006-05-25 | 2007-12-06 | Mallik Sundaram | Low molecular weight heparin composition and uses thereof |
| CN101711771B (zh) * | 2008-10-07 | 2015-12-09 | 上海喜恩医药科技发展有限公司 | 一种肝素衍生的多糖混合物及其制法和药物组合物 |
| CN103209997B (zh) * | 2010-09-14 | 2016-03-16 | 国立大学法人宫崎大学 | 高纯度肝素及其制备方法 |
| WO2012072799A1 (en) | 2010-12-02 | 2012-06-07 | Aventis Pharma S.A. | New methods for the in vitro measurement of the biological activity of an ultra low molecular weight heparin sample |
| CN102558392A (zh) * | 2010-12-14 | 2012-07-11 | 王芃 | 一种高抗FXa、低抗FIIa低分子肝素钠的制备方法 |
| CN102816255B (zh) * | 2011-06-10 | 2015-11-25 | 王芃 | 一种超低分子肝素钠的制备方法 |
| US9896517B2 (en) | 2013-03-26 | 2018-02-20 | Jiuzhitang Co., Ltd. | Low molecular weight glycosaminoglycan derivative, pharmaceutical composition thereof, preparation method therefor and use thereof |
| CN103864959A (zh) * | 2014-04-03 | 2014-06-18 | 中国药科大学 | 一种肝素十二糖抗动脉粥样硬化的用途 |
| RU2639574C2 (ru) * | 2016-05-23 | 2017-12-21 | Алексей Георгиевич Александров | Способ получения низкомолекулярного гепарина |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL61201A (en) * | 1979-10-05 | 1984-09-30 | Choay Sa | Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them |
| FR2504928A1 (fr) * | 1981-04-29 | 1982-11-05 | Choay Sa | Oligosaccharides a chaines courtes possedant des proprietes biologiques, leur preparation et leurs applications en tant que medicaments |
| FR2669932B1 (fr) * | 1990-12-03 | 1994-07-01 | Sanofi Sa | Nouvel heparosane-n,o-sulfate, son procede de preparation et les compositions pharmaceutiques qui le contiennent. |
| IT1284143B1 (it) * | 1996-09-06 | 1998-05-08 | Istituto Scient Di Chimica E B | Eparansolfati semi-sintetici ad elevata attivita' antimetastica e ridotto rischio emorragico |
| WO1998055515A1 (en) * | 1997-06-06 | 1998-12-10 | Hamilton Civic Hospitals Research Development, Inc. | Modified low molecular weight heparin that inhibits clot associated coagulation factors |
| ES2161615B1 (es) * | 1999-07-23 | 2003-03-16 | Rovi Lab Farmaceut Sa | Composiciones de heparinas de muy bajo peso molecular. |
| JP4897991B2 (ja) * | 1999-07-23 | 2012-03-14 | ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ | 超低分子量ヘパリン組成物 |
| FR2800074B1 (fr) * | 1999-10-22 | 2001-12-21 | Aventis Pharma Sa | Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant |
| JP4585072B2 (ja) * | 2000-02-29 | 2010-11-24 | 扶桑薬品工業株式会社 | ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物 |
| FR2807043B1 (fr) * | 2000-03-28 | 2002-11-22 | Aventis Pharma Sa | Composition pharmaceutique contenant des oligosaccharides, les nouveaux oligosaccharides et leur preparation |
| FR2811992B1 (fr) * | 2000-07-21 | 2003-07-04 | Aventis Pharma Sa | Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant |
| US6969705B2 (en) * | 2000-07-21 | 2005-11-29 | Aventis Pharma S.A. | Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
| JP2005505537A (ja) * | 2001-08-28 | 2005-02-24 | レオ・ファーマ・アクティーゼルスカブ | 低分子量ヘパリンと低分子量デルマタン硫酸とを含む抗血栓組成物 |
| FR2845686B1 (fr) * | 2002-10-10 | 2013-08-30 | Aventis Pharma Sa | Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant |
-
2003
- 2003-07-24 FR FR0309041A patent/FR2857971B1/fr not_active Expired - Fee Related
-
2004
- 2004-07-01 PE PE2004000632A patent/PE20050246A1/es not_active Application Discontinuation
- 2004-07-14 PA PA20048606801A patent/PA8606801A1/es unknown
- 2004-07-19 AR ARP040102549A patent/AR045917A1/es not_active Application Discontinuation
- 2004-07-21 HN HN2004000250A patent/HN2004000250A/es unknown
- 2004-07-22 RU RU2006105384/04A patent/RU2346005C2/ru not_active IP Right Cessation
- 2004-07-22 BR BRPI0412850-8A patent/BRPI0412850A/pt active Search and Examination
- 2004-07-22 MX MXPA06000336A patent/MXPA06000336A/es active IP Right Grant
- 2004-07-22 CN CN2004800265420A patent/CN1852926B/zh not_active Expired - Fee Related
- 2004-07-22 DE DE602004030015T patent/DE602004030015D1/de not_active Expired - Lifetime
- 2004-07-22 RS YUP-2006/0044A patent/RS20060044A/sr unknown
- 2004-07-22 AT AT04785991T patent/ATE487741T1/de active
- 2004-07-22 PL PL04785991T patent/PL1651677T3/pl unknown
- 2004-07-22 PT PT04785991T patent/PT1651677E/pt unknown
- 2004-07-22 OA OA1200600025A patent/OA13197A/fr unknown
- 2004-07-22 AU AU2004259111A patent/AU2004259111B2/en not_active Ceased
- 2004-07-22 JP JP2006520862A patent/JP4865552B2/ja not_active Expired - Fee Related
- 2004-07-22 ES ES04785991T patent/ES2355827T3/es not_active Expired - Lifetime
- 2004-07-22 UA UAA200601969A patent/UA89356C2/ru unknown
- 2004-07-22 DK DK04785991.3T patent/DK1651677T3/da active
- 2004-07-22 EP EP04785991A patent/EP1651677B1/fr not_active Expired - Lifetime
- 2004-07-22 MY MYPI20042944A patent/MY136769A/en unknown
- 2004-07-22 NZ NZ544717A patent/NZ544717A/en unknown
- 2004-07-22 WO PCT/FR2004/001943 patent/WO2005010051A2/fr not_active Ceased
- 2004-07-22 CA CA002533555A patent/CA2533555A1/fr not_active Abandoned
- 2004-07-22 ME MEP-116/08A patent/MEP11608A/xx unknown
- 2004-07-22 KR KR1020067001609A patent/KR101125517B1/ko not_active Expired - Fee Related
- 2004-07-22 SI SI200431594T patent/SI1651677T1/sl unknown
- 2004-07-23 GT GT200400145A patent/GT200400145A/es unknown
- 2004-07-23 TW TW093121979A patent/TWI369208B/zh not_active IP Right Cessation
- 2004-07-23 UY UY28435A patent/UY28435A1/es unknown
-
2006
- 2006-01-17 IL IL173206A patent/IL173206A/en not_active IP Right Cessation
- 2006-01-18 CR CR8201A patent/CR8201A/es unknown
- 2006-01-20 MA MA28745A patent/MA27928A1/fr unknown
- 2006-01-23 ZA ZA200600657A patent/ZA200600657B/en unknown
- 2006-01-23 EC EC2006006305A patent/ECSP066305A/es unknown
- 2006-01-23 TN TNP2006000025A patent/TNSN06025A1/en unknown
- 2006-02-20 NO NO20060821A patent/NO20060821L/no not_active Application Discontinuation
-
2011
- 2011-02-04 CY CY20111100132T patent/CY1111165T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN05101A1 (fr) | Melanges de polysaccharides derives d'heparine leur preparation et les compositions pharmaceutiques les contenant | |
| Nahain et al. | Heparin mimetics with anticoagulant activity | |
| Mourão | Use of sulfated fucans as anticoagulant and antithrombotic agents: future perspectives | |
| AR045917A1 (es) | Mezclas de oligosacaridos derivados de la heparina, su preparacion y las composiciones farmaceuticas que las contienen | |
| Mourão et al. | Antithrombotic activity of a fucosylated chondroitin sulphate from echinoderm: sulphated fucose branches on the polysaccharide account for its antithrombotic action | |
| Damonte et al. | Sulfated seaweed polysaccharides as antiviral agents | |
| Mourão et al. | Inactivation of thrombin by a fucosylated chondroitin sulfate from echinoderm | |
| Kuo | Practical aspects of hyaluronan based medical products | |
| Liu et al. | Hyaluronate‐heparin conjugate gels for the delivery of basic fibroblast growth factor (FGF‐2) | |
| Casu et al. | Structural and conformational aspects of the anticoagulant and antithrombotic activity of heparin and dermatan sulfate | |
| RU2010122324A (ru) | Полисахаридные композиции, не обладающие антикоагулянтными свойствами | |
| SI2794667T1 (en) | Low anticoagulant heparins | |
| Mohamed et al. | Synthetic approaches to L-iduronic acid and L-idose: Key building blocks for the preparation of glycosaminoglycan oligosaccharides | |
| KR900702372A (ko) | 참게 아메보사이트 라이세이트 g인자 활성화 저해제 | |
| RU2216548C2 (ru) | Смесь линейных олигосахаридов, полученная из дерматансульфата, фармацевтическая композиция, обладающая антитромботическим действием, и способ лечения | |
| ES2687900T3 (es) | Derivados de glicosaminoglicanos N-desulfatados y su uso como fármacos | |
| JP2004210715A5 (es) | ||
| RU2016116786A (ru) | Иммуностимулятор | |
| Ludwig et al. | Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities | |
| CA2932987C (en) | Combination of glycosaminoglycans and cyclodextrins | |
| Pavão | Structure and anticoagulant properties of sulfated glycosaminoglycans from primitive Chordates | |
| AR041555A1 (es) | Mezclas de polisacaridos derivados de heparina, su preparacion y las composiciones farmaceuticas que las contienen | |
| TW200704403A (en) | Dilution resistant viscoelastic compositions | |
| Calabrese et al. | A small fraction of dermatan sulfate with significantly increased anticoagulant activity was selected by interaction with the first complement protein | |
| TW200745154A (en) | Oligosaccharides derived from fucoidan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |